Search clinical trials for: peritoneal malignant mesothelioma

Total 7606 results

University Health Network, Toronto

Active, not recruiting

Short Neoadjuvant Hemithoracic IMRT for MPM

Malignant Pleural Mesothelioma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
TCR2 Therapeutics

Active, not recruiting

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Cholangiocarcinoma | Triple Negative Breast Cancer | Ovarian Adenocarcinoma | Mesotheliomas Pleural and other conditions

United States
TCR2 Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Cholangiocarcinoma | Non Small Cell Lung Cancer Metastatic | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma; Pleura | Cholangiocarcinoma Recurrent | High Grade Ovarian Serous Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Åslaug Helland
Bristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASA

Active, not recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; Lung

Norway, Denmark, Sweden, Spain, Australia
Verastem, Inc.

Terminated

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Malignant Pleural Mesothelioma

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; AstraZeneca

Active, not recruiting

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Malignant Neoplasms of Female Genital Organs

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Pleural Malignant Mesothelioma

United States
M.D. Anderson Cancer Center

Completed

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

Malignant Solid Neoplasm | Gastric Carcinoma | Malignant Peritoneal Neoplasm | Colorectal Carcinoma | Carcinomatosis | Appendix Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Genelux Corporation

Active, not recruiting

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Lung Cancer

United States
Capital Medical University

Terminated

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Cancer | Mesothelioma, Malignant

China
National Cancer Institute (NCI)

Terminated

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Mesothelioma

United States
National Cancer Institute (NCI)

Withdrawn

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Malignant Pleural Mesotheliomas (Mpm) | Malignant Pleural Effusions (Mpe) | Epithelial Tumors, Malignant | Pleural Effusions, Malignant | Mesothelin (Msln)

United States
Amphera BV
TMC Pharma

Completed

DENdritic Cell Immunotherapy for Mesothelioma (DENIM)

Mesothelioma

Netherlands, France, United Kingdom, Belgium, Italy
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma

United States
Dana-Farber Cancer Institute
AstraZeneca

Suspended

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Mesothelioma

United States
Canadian Cancer Trials Group
Merck Sharp & Dohme LLC; Intergroupe Francophone de Cancerologie Thoracique; National...

Active, not recruiting

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Mesothelioma

France, Canada, Italy
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Pleural Malignant Mesothelioma

United States, Canada
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Dose Individualization of Pemetrexed - IMPROVE-I (IMPROVE-I)

Non Small Cell Lung Cancer | Mesothelioma

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma

Lung Cancer | Unresectable Mesothelioma

United States
PrECOG, LLC.
AstraZeneca; University of Sydney; Thoracic Oncology Group Australasia (TOGA)

Active, not recruiting

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Mesothelioma

United States, Australia, New Zealand
University of Washington
National Cancer Institute (NCI)

Terminated

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Ovarian... and other conditions

United States
Roswell Park Cancer Institute
Lumeda,Inc.

Active, not recruiting

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Malignant Mesothelioma | Non-Small Cell Lung Carcinoma | Pleural Disorder

United States
NRG Oncology
National Cancer Institute (NCI)

Terminated

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...

United States, Canada
Turnstone Biologics, Corp.
Takeda

Terminated

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR)

Renal Cell Carcinoma | Cervical Cancer | Solid Tumor | Mesothelioma | Melanoma (Skin) | Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Microsatellite Stable Colorectal Cancer | Cutaneous Squamous Cell Carcinoma

United States, Canada, Korea, Republic of
University Health Network, Toronto

Active, not recruiting

A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (SMARTER)

Mesothelioma; Lung

Canada
Massachusetts General Hospital
Conquer Cancer Foundation

Active, not recruiting

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (UPLIFT)

Stage IV Non-Small Cell Lung Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Immunotherapy | Immune Checkpoint Inhibitors | Stage IV Gastric Cancer | Stage IV Merkel Cell Carcinoma | Stage IV Colorectal Cancer | Stage IV Esophageal Cancer | Advanced Lung Cancer | Stage IV Renal... and other conditions

United States
Groupe Français de Pneumo-Cancérologie
Bristol-Myers Squibb

Active, not recruiting

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) (MESO-IMMUNE)

Malignant Pleural Mesothelioma | Unresectable Malignant Neoplasm

France
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Malignant Mesothelioma (MPM)

United States
Polaris Group

Completed

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC)

Mesothelioma

United States, United Kingdom, Taiwan, Australia, Italy
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
University Hospital, Toulouse

Completed

Rehabilitation by Effort for Patients With Advanced Bronchial Cancer (RehabKBP)

Malignant Mesothelioma | Bronchial Cancer

France
University of Florida
GlaxoSmithKline

Completed

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Renal Cell Carcinoma | Mesothelioma | Cholangiocarcinoma | Uveal Melanoma

United States
University of Hull

Completed

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years (CanBenefitII)

Lung Neoplasm Malignant | Mesothelioma; Lung

United Kingdom
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

United States
University of Chicago

Suspended

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

Gastric Cancers

United States
University of Chicago

Suspended

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Brenner Tumor | Malignant Ascites | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer and other conditions

United States
Canadian Cancer Trials Group
National Cancer Institute (NCI); Cancer Research UK; Grupo Español de Investigación... and other collaborators

Completed

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Metastatic Cancer

Canada, Spain, United States, United Kingdom
Candel Therapeutics, Inc.
University of Pennsylvania

Completed

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion (MpeTK01)

Breast Cancer | Ovarian Cancer | Lung Cancer | Mesothelioma | Malignant Pleural Effusion

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME)

Advanced Malignant Pleural Mesothelioma

United Kingdom
NCIC Clinical Trials Group
Pfizer

Completed

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

Canada
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
PrECOG, LLC.
AstraZeneca

Completed

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)

Mesothelioma | Pleural Mesothelioma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); North Central Cancer Treatment Group

Completed

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Mesothelioma

United States
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
National Cancer Institute (NCI)

Terminated

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Lung Cancer | Carcinoma, Esophageal | Malignant Pleural Mesotheliomas

United States
University Hospital, Antwerp

Completed

Dendritic Cell Vaccination for Patients With Solid Tumors

Renal Cell Carcinoma | Glioblastoma | Malignant Mesothelioma | Colorectal Tumors | Breast Cancers | Sarcomas

Belgium
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States

Search clinical trials for: peritoneal malignant mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations